Repligen (RGEN) Competitors $132.87 +1.19 (+0.90%) Closing price 04:00 PM EasternExtended Trading$132.85 -0.02 (-0.01%) As of 05:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RGEN vs. BIIB, UTHR, INCY, NBIX, EXEL, BMRN, EXAS, HALO, MDGL, and IONSShould you be buying Repligen stock or one of its competitors? The main competitors of Repligen include Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), Neurocrine Biosciences (NBIX), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Halozyme Therapeutics (HALO), Madrigal Pharmaceuticals (MDGL), and Ionis Pharmaceuticals (IONS). These companies are all part of the "biotechnology" industry. Repligen vs. Biogen United Therapeutics Incyte Neurocrine Biosciences Exelixis BioMarin Pharmaceutical Exact Sciences Halozyme Therapeutics Madrigal Pharmaceuticals Ionis Pharmaceuticals Biogen (NASDAQ:BIIB) and Repligen (NASDAQ:RGEN) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, community ranking, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk. Does the MarketBeat Community believe in BIIB or RGEN? Biogen received 1406 more outperform votes than Repligen when rated by MarketBeat users. Likewise, 71.28% of users gave Biogen an outperform vote while only 67.09% of users gave Repligen an outperform vote. CompanyUnderperformOutperformBiogenOutperform Votes182471.28% Underperform Votes73528.72% RepligenOutperform Votes41867.09% Underperform Votes20532.91% Which has better valuation & earnings, BIIB or RGEN? Biogen has higher revenue and earnings than Repligen. Repligen is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiogen$9.82B2.03$1.63B$10.1313.44Repligen$650.43M11.50$35.60M-$0.45-295.93 Do analysts rate BIIB or RGEN? Biogen presently has a consensus price target of $191.30, indicating a potential upside of 40.48%. Repligen has a consensus price target of $173.25, indicating a potential upside of 30.10%. Given Biogen's higher possible upside, equities analysts plainly believe Biogen is more favorable than Repligen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biogen 0 Sell rating(s) 20 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.38Repligen 0 Sell rating(s) 5 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.64 Does the media refer more to BIIB or RGEN? In the previous week, Repligen had 1 more articles in the media than Biogen. MarketBeat recorded 9 mentions for Repligen and 8 mentions for Biogen. Biogen's average media sentiment score of 1.20 beat Repligen's score of 0.68 indicating that Biogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Repligen 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Do insiders & institutionals believe in BIIB or RGEN? 87.9% of Biogen shares are owned by institutional investors. Comparatively, 97.6% of Repligen shares are owned by institutional investors. 0.2% of Biogen shares are owned by insiders. Comparatively, 1.2% of Repligen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has more risk & volatility, BIIB or RGEN? Biogen has a beta of 0.14, suggesting that its share price is 86% less volatile than the S&P 500. Comparatively, Repligen has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500. Is BIIB or RGEN more profitable? Biogen has a net margin of 16.87% compared to Repligen's net margin of -4.64%. Biogen's return on equity of 14.98% beat Repligen's return on equity.Company Net Margins Return on Equity Return on Assets Biogen16.87% 14.98% 8.76% Repligen -4.64%4.21%2.94% SummaryBiogen beats Repligen on 12 of the 18 factors compared between the two stocks. Get Repligen News Delivered to You Automatically Sign up to receive the latest news and ratings for RGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RGEN vs. The Competition Export to ExcelMetricRepligenBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.49B$3.12B$5.57B$8.66BDividend YieldN/A1.59%5.27%4.19%P/E Ratio-261.5433.7427.3420.20Price / Sales11.50486.59415.29164.38Price / Cash53.61168.6838.2534.64Price / Book3.783.507.174.73Net Income$35.60M-$72.35M$3.23B$248.00M7 Day Performance7.05%11.26%6.74%4.53%1 Month Performance8.06%25.20%15.54%10.88%1 Year Performance-5.71%-14.66%32.85%15.20% Repligen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RGENRepligen4.8297 of 5 stars$132.87+0.9%$173.25+30.4%-9.7%$7.47B$650.43M-260.532,020BIIBBiogen4.7977 of 5 stars$131.14+1.0%$191.30+45.9%-40.5%$19.22B$9.82B11.728,720Positive NewsUTHRUnited Therapeutics4.965 of 5 stars$325.48+2.1%$393.00+20.7%+19.4%$14.68B$2.99B14.29980Positive NewsAnalyst RevisionGap DownINCYIncyte4.2909 of 5 stars$65.31+0.4%$73.60+12.7%+18.1%$12.64B$4.41B241.902,320Positive NewsNBIXNeurocrine Biosciences4.9498 of 5 stars$124.56+1.3%$162.00+30.1%-6.8%$12.33B$2.41B37.861,200Analyst RevisionEXELExelixis4.5476 of 5 stars$42.88-0.4%$38.94-9.2%+96.2%$11.69B$2.30B24.231,220Positive NewsBMRNBioMarin Pharmaceutical4.8966 of 5 stars$57.05-1.8%$93.45+63.8%-29.5%$10.94B$2.95B25.933,080Positive NewsAnalyst RevisionEXASExact Sciences4.3813 of 5 stars$56.13-0.3%$70.90+26.3%+27.3%$10.59B$2.83B-10.086,400Positive NewsHALOHalozyme Therapeutics4.8647 of 5 stars$55.64-0.8%$61.90+11.3%+6.9%$6.86B$1.08B16.22390MDGLMadrigal Pharmaceuticals4.2548 of 5 stars$272.67-0.9%$416.33+52.7%+14.7%$6.05B$317.38M-10.8790Positive NewsAnalyst RevisionIONSIonis Pharmaceuticals4.2782 of 5 stars$34.11+1.8%$56.67+66.1%-5.6%$5.43B$717.25M-11.22800 Related Companies and Tools Related Companies Biogen Alternatives United Therapeutics Alternatives Incyte Alternatives Neurocrine Biosciences Alternatives Exelixis Alternatives BioMarin Pharmaceutical Alternatives Exact Sciences Alternatives Halozyme Therapeutics Alternatives Madrigal Pharmaceuticals Alternatives Ionis Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RGEN) was last updated on 6/10/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredWhy 2026 will be a disaster for many Americans2025 Market Crash The first-quarter stock crash left investors wondering what lies ahead. Today 50-year Wal...Chaikin Analytics | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Repligen Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Repligen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RGEN Stock Free RGEN Stock Alerts